Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 19/20 | 0.55 |
| ▸ | FKBP5 | Q13451 | 7/20 | 0.53 |
| ▸ | FKBP4 | Q02790 | 3/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21643553 | 1.00 | FKBP1A (0.55) | FKBP1AFKBP5FKBP4 | |
| SCHEMBL15804440 | 0.91 | LMNA (0.48) | FKBP1AFKBP5FKBP4 | |
| SCHEMBL10027119 | 0.91 | STAT3 (0.48) | FKBP1A | |
| SCHEMBL21643350 | 0.89 | LMNA (0.50) | FKBP1AFKBP5FKBP4 | |
| SCHEMBL21643353 | 0.89 | LMNA (0.50) | FKBP1AFKBP5FKBP4 | |
| SCHEMBL19230453 | 0.88 | FKBP1A (0.47) | FKBP1AFKBP5FKBP4 | |
| SCHEMBL1775476 | 0.87 | STAT3 (0.51) | FKBP1A | |
| SCHEMBL15049104 | 0.86 | FKBP1A (0.46) | FKBP1AFKBP5FKBP4 | |
| SCHEMBL16687900 | 0.86 | SMN1; SMN2 (0.52) | FKBP1A | |
| SCHEMBL16158169 | 0.86 | FKBP1A (0.46) | FKBP1AFKBP5FKBP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239810-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2024-07-18 | — | — | US | disclosed |
| US-11945827-B2 | Rapafucin derivative compounds and methods of use thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2024-04-02 | — | — | US | disclosed |
| US-20230000996-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2023-01-05 | — | — | US | disclosed |
| US-11066416-B2 | Rapafucin derivative compounds and methods of use thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-07-20 | — | — | US | disclosed |
| WO-2021067439-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-04-08 | — | — | WO | disclosed |
| US-20210094933-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2021-04-01 | — | — | US | disclosed |
| US-20200308144-A1 | Multimeric piperidine derivatives | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2020-10-01 | — | — | US | disclosed |
| US-20200040004-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RAPAFUSYN PHARMACEUTICALS, INC. | 2020-02-06 | — | — | US | disclosed |
| US-9573934-B2 | Methods and compositions for the synthesis of multimerizing agents | ARIAD PHARMACEUTICALS, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-9573934-B2 | Methods and compositions for the synthesis of multimerizing agents | ARIAD PHARMACEUTICALS, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-20140171649-A1 | Methods and Compositions for the Synthesis of Multimerizing Agents | ARIAD PHARMACEUTICALS, INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-20140171649-A1 | Methods and Compositions for the Synthesis of Multimerizing Agents | ARIAD PHARMACEUTICALS, INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-8436183-B2 | Synthetic multimerizing agents | ARIAD PHARMACEUTICALS, INC. (US) | 2013-05-07 | — | — | US | disclosed |
| WO-2012103279-A2 | METHODS AND COMPOSITIONS FOR THE SYNTHESIS OF MULTIMERIZING AGENTS | ARIAD PHARMACEUTICALS, INCORPORATED (US) | 2012-08-02 | — | — | WO | disclosed |
| US-20120130076-A1 | Synthetic Multimerizing Agents | ARIAD PHARMACEUTICALS, INC. (US) | 2012-05-24 | — | — | US | disclosed |
| EP-0888303-B1 | SYNTHETIC DERIVATIVES OF RAPAMYCIN AS MULTIMERIZING AGENTS FOR CHIMERIC PROTEINS WITH IMMUNOPHILIN-DERIVED DOMAINS | ARIAD PHARMA INC (US) | 2010-04-21 | — | — | EP | disclosed |
| US-20040006233-A1 | Synthetic multimerizing agents | ARIAD PHARMACEUTICALS, INC. | 2004-01-08 | — | — | US | disclosed |
| US-20020161240-A1 | Synthetic multimerizing agents | ARIAD GENE THERAPEUTICS, INC. | 2002-10-31 | — | — | US | disclosed |
| US-6150527-A | Synthetic multimerizing agents | ARIAD PHARMACEUTICALS, INC. (US) | 2000-11-21 | — | — | US | disclosed |
| US-6133456-A | DIMERS OF THE MACROCYCLIC NATURAL PRODUCT, FK506, COVALENTLY ATTACHED TO EACH OTHER VIA A SYNTHETIC LINKER MOIETY | ARIAD GENE THERAPEUTICS, INC. (US) | 2000-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140171649-A1 | Methods and Compositions for the Synthesis of Multimerizing Agents | PIP5K1C, PIP4K2C, IPMK | FKBP1A 3612/4885FKBP5 3703/4885FKBP4 4458/4885 |
| US-11066416-B2 | Rapafucin derivative compounds and methods of use thereof | RICTOR, FKBP14, MTOR | FKBP1A 9/4885FKBP5 11/4885FKBP4 7/4885 |
| US-20020161240-A1 | Synthetic multimerizing agents | SSB, F13B, LCP2 | FKBP1A 924/4885FKBP5 1724/4885FKBP4 1799/4885 |
| US-20200308144-A1 | Multimeric piperidine derivatives | FKBP14, FKBP5, FKBP3 | FKBP1A 4/4885FKBP5 2/4885FKBP4 7/4885 |
| US-20200040004-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RICTOR, FKBP14, MTOR | FKBP1A 9/4885FKBP5 11/4885FKBP4 7/4885 |
| US-20120130076-A1 | Synthetic Multimerizing Agents | FKBP1B, FKBP2, FKBP14 | FKBP1A 4/4885FKBP5 5/4885FKBP4 7/4885 |
| US-20040006233-A1 | Synthetic multimerizing agents | FKBP1B, FKBP2, FKBP14 | FKBP1A 4/4885FKBP5 6/4885FKBP4 7/4885 |
| US-20230000996-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RICTOR, FKBP14, MTOR | FKBP1A 9/4885FKBP5 11/4885FKBP4 7/4885 |
| US-20210094933-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RICTOR, FKBP14, MTOR | FKBP1A 9/4885FKBP5 11/4885FKBP4 7/4885 |
| US-11945827-B2 | Rapafucin derivative compounds and methods of use thereof | RICTOR, FKBP14, MTOR | FKBP1A 9/4885FKBP5 11/4885FKBP4 7/4885 |
| US-20240239810-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RICTOR, MTOR, FKBP14 | FKBP1A 10/4885FKBP5 16/4885FKBP4 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.